RAPID COMMUNICATION
Relative Insensitivity to Fas Ligand |
| |
Abstract |
|---|
|
|
|---|
CD8+ T cells appear to play an important pathophysiologic role in many inflammatory lung diseases. The
primary effector function of this T-cell subset is cytolysis of virus-infected cells, and it is widely believed
that there are two primary molecular mechanisms by which this occurs: the perforin/granzyme-mediated
pathway of cytolysis, and the Fas ligand (FasL)-Fas (CD95/APO-1) pathway of induction of target-cell
apoptosis. This conclusion is based primarily on data obtained with hematopoetic cell lines as target cells.
There is also a growing body of evidence that Fas is involved in the transduction of apoptotic signals in a
variety of inflammatory disease states, particularly involving the liver and the lung. In the study reported
here we took advantage of a novel in vitro assay to directly assess the effector mechanisms employed in CD8+
T-cell-mediated cytolysis of alveolar epithelial cells. We present evidence that FasL-induced, Fas-mediated
apoptosis does not directly contribute to T-cell-mediated cytolysis of alveolar epithelial-derived cells, even
though Fas is expressed and functional on these cells. We also demonstrated that the perforin-independent
cytolytic activity of CD8+ T cells against alveolar epithelial-derived cells is explained entirely by tumor necrosis factor-
(TNF-
), which is expressed on CD8+ T cells. Furthermore, we show that bystander cytolysis of alveolar epithelial-derived cells by antiviral CD8+ T cells is entirely perforin-independent. This activity is mediated exclusively by TNF-
. Both alveolar epithelial-derived cells and primary murine type II
cells show susceptibility to apoptosis triggered by soluble TNF-
, without the need for transcriptional or
translational inhibition. We also confirmed the resistance of alveolar type II cells to FasL in vivo by performing adoptive transfer of perforin-deficient antiviral CD8+ T cells into transgenic mice expressing a
target antigen in type II epithelial cells. Significant lung injury developed in the transgenic CD8+ T-cell recipients, whether or not Fas was expressed in these animals. Furthermore, preincubation of the T cells with
antibody to TNF-
completely abolished the injury. These results suggest that alveolar epithelial cells are
relatively sensitive to T cell-triggered, TNF-
-mediated apoptosis, and resistant to apoptosis triggered by
FasL. These observations may have important ramifications for understanding of the pathophysiology of
interstitial and inflammatory lung diseases.
| |
Introduction |
|---|
|
|
|---|
A number of inflammatory lung diseases are presumed to be T-cell mediated, and are characterized by the accumulation of T cells in the alveolar space or in the interstitium (1). The role(s) that CD8+ T cells play in the pathogenesis of interstitial lung disease is unclear, as is the nature of the effector function(s) expressed at the sites of inflammatory activity. CD8+ T cells express potent cytotoxic activity, which appears to function primarily in the clearance of virus infection (5). In vitro analysis of antiviral activity of CD8+ T cells strongly suggests that cytolytic activity is both necessary and sufficient to effect the lysis of virus- infected target cells (12). Several groups have shown that CD8+ T cells utilize two primary molecular mechanisms to induce target cell death: the perforin/granzyme-mediated pathway of cytolysis and the Fas ligand (FasL)- Fas (CD95) pathway of induction of target-cell apoptosis. In the absence of both of these mechanisms, there is no cytolysis of conventional target cells, which are generally of hematopoetic origin (12, 13, 15). The molecular basis of T-cell-mediated cytolysis of respiratory cells has not been directly addressed, but the issue is an important one, since the respiratory tract is a frequent target of virus infection.
Initial interest in Fas focused on its role in maintenance
of the lymphoid compartment (20). However, over the
past several years, there has been intensified interest in extralymphoid expression of Fas and its potential participation in tissue inflammation and injury. In particular, numerous reports have suggested a role for Fas in chronic
inflammatory liver disease (26), thyroiditis (34, 35), experimental diabetes (36), and lung disease. The literature
on participation of Fas in lung disease is replete with demonstrations of expression of Fas in clinical (37) and experimental specimens (41, 42). In addition, several intriguing studies have involved the experimental induction of
pneumonitis (43) and type II cell apoptosis by ligation of
Fas by agonist antibodies (44, 45). There is so far no direct
evidence that Fas-mediated apoptosis plays a role in lung
injury mediated by FasL-expressing T cells. Several lines
of evidence have, however, suggested that tumor necrosis
factor (TNF)-
has a primary or secondary role in pulmonary inflammation (46), though not specifically in injury mediated directly by T cells. TNF-
is a minor contributor to T-cell effector function, and has not been
shown to participate in acute cytolysis of conventional target cells (49). In the present study, we took advantage of a
novel in vitro assay to present evidence that alveolar epithelial-derived cells are susceptible to CD8+ T-cell-triggered apoptosis induced by TNF-
, but are resistant to apoptotic signals triggered by FasL. We also showed that
perforin-independent, T-cell-mediated cytotoxicity of alveolar epithelial-derived cells is mediated entirely and exclusively by TNF-
. Furthermore, using a transgenic model
of T-cell-mediated lung injury (50, 51), we showed in vivo
that Fas-deficient animals are not protected against injury
by activated CD8+ T cells, even when the T cells are derived from perforin-deficient animals, whereas pretreatment of T cells with antibody to TNF-
abolishes lung injury induced by perforin-deficient T cells.
| |
Materials and Methods |
|---|
|
|
|---|
Alveolar Epithelial-Derived Cells
MLE-15 cells (52) were transfected with the class I major histocompatibility complex (MHC) molecule, Kd (construct provided by Dr. Michael Bevan, University of Washington, Seattle, WA). The transfectants were stained with SF1.1 (anti-Kd; American Type Culture Collection [ATCC], Rockville, MD) and TIB95 (anti-Kq, the native haplotype of the parental line; ATCC), and sorted by flow cytometry according to their level of Kd expression with a FACScan instrument using CellQuest software (Becton-Dickinson, Palo Alto, CA). The cells were then cloned by limiting dilution, and were passaged twice a week.
T-Cell Cytotoxicity Assay
The CD8+ T-cell clones used in our experiments were generated by limiting dilution as previously described (53),
from either wild-type or perforin-deficient mice (18). The
clones were restimulated weekly in vitro with irradiated
syngeneic splenocytes that were infected with A/Japan/57
influenza virus, and were placed into fresh Iscove's complete medium supplemented with 10 IU/ml of interleukin (IL)-2. On Day 5 after in vitro stimulation, T cells were
tested with a 51Cr release assay for cytolytic activity
against target cells infected with A/Japan/57 or against target cells loaded with 10
9 M synthetic peptide representing the 210-219 epitope of the A/Japan/57 hemagglutinin
(HA) (50). The target cells used were MLE-Kd cells and
L121+ cells, the latter of which are transfected with a Fas-
overexpression construct (54). In some experiments, the
anti-Fas monoclonal antibody MFL3 was added to wells at
a final concentration of 5 µg/ml, or anti-TNF-
antiserum
(IP400, Genzyme, Boston, MA) was added at a final dilution of 1:100. Cytotoxicity assays were conducted for 6 h in
96-well plates with a final volume of 0.2 ml/well of target
and effector cells in culture medium, after which 0.1 ml was harvested and counted on a gamma counter (Isomedic; ICN Biomedicals, Inc., Costa Mesa, CA). Percent
specific 51Cr release was calculated according to the formula: (test cpm
spontaneous release cpm)/(total cpm
spontaneous cpm) × 100. Spontaneous release from targets incubated with medium alone was always less than
10%. Specific lysis values represent the mean percent specific 51Cr release from four replicate wells.
DNA Fragmentation Assay
MLE-Kd cells were labeled with tritiated thymidine for 6 h
and were then incubated for 24 h with 0.01 µg/ml Jo-2 antibody (PharMingen, San Diego, CA) or with an isotype-
matched control hamster antibody (MFL3), with or without 20 µg/ml protein G (Sigma, St. Louis, MO). The cells
were then lysed and harvested. L1210+ and L1210
cells,
which are transfected with a Fas-overexpression or antisense construct, respectively (54), were similarly treated
and were used as controls. In some experiments, soluble
TNF-
(Genzyme, Boston, MA) was added to MLE-Kd
cells at varying concentrations for 6 h prior to harvesting
(5 × 107 U/mg). Percent DNA fragmentation was calculated as described (55) according to the formula: (total
cpm [immediately after labeling]
test cpm)/total cpm × 100. All values represent the mean of four replicate wells.
Primary Type II Pneumocyte DNA Fragmentation
Primary alveolar type II cells were prepared according
to a modification of a previously published method (56).
Briefly, BALB/c mice were anesthetized and exsanguinated by severing the inferior vena cava and left renal
artery. The tracheae were exposed and cannulated, and
the lungs were perfused with 10-20 ml sterile saline via
the pulmonary artery until visually free of blood. Dispase
(Collaborative Research, Inc., Bedford, MA) was instilled into the lungs via the tracheal catheter, and was followed
by 1% low melting agarose, warmed to 45°C. The lungs
were immediately covered with ice and incubated for 2 min
to gel the agarose. Lungs were then dissected free of the
animal, put in a culture tube containing an additional 1 ml
of Dispase, and incubated for 45 min at room temperature.
Lungs were then transferred to a culture dish containing
deoxyribonuclease (DNAse) I (Sigma, St. Louis, MO) and
the tissue was gently teased away from the airways. The cell suspension was successively filtered and then pelleted.
Crude cell suspensions were added to culture dishes coated
with anti-CD45 and anti-CD32 antibodies (PharMingen)
and incubated for 1-2 h. Plates were removed from the incubator and gently "panned" to free settled type II cells,
which were resuspended in Dulbecco's modified Eagle's
medium with 10% fetal bovine serum. Purity of the type II
cell preparations used for these studies was 92 ± 1% according to morphologic criteria (56), and cell viability determined by Trypan blue exclusion after overnight incubation was > 60%. (Purity for more than 100 separate preparations was consistently > 90%.) Cells were plated in 96-well
plates and labeled overnight with tritiated thymidine. The
wells were washed to remove unincorporated label and
nonadherent cells, and the remaining cells were then incubated for 6 h with TNF-
. The percent DNA fragmentation was calculated as described (55), and represents the
mean of four replicate wells.
Adoptive Transfer
SPC-HA transgenic mice (H-2d) expressing the A/Japan/
305/57 influenza HA under the transcriptional control of
the surfactant protein-C (SP-C) promoter were used in
these studies (50). Transgene-negative littermates were
used as control recipients. Animals subjected to adoptive
transfer were used at 10-12 wk of age (18-22 g). Fas-deficient (lpr) animals in the H-2d haplotype (generously provided by Dr. Philip Cohen of the University of North
Carolina, Chapel Hill, NC) were bred with the SPC-HA transgenic mice for use in some experiments. The offspring were screened for the HA transgene as described
(50), and for the lpr mutation with a three-primer polymerase chain reaction (PCR) method as described (57).
The CD8+ cytolytic T-cell clone 40-2 was restimulated in
vitro with irradiated syngeneic splenocytes that were infected with A/Japan/57 influenza virus. On Day 5 after
stimulation, clones were separated from stimulators by
density gradient centrifugation and were injected via the
tail vein into appropriate recipient animals. In some instances, T cells were preincubated with anti-TNF-
antibody (1:100, IP400; Genzyme) for 30 min at 4°C and were
then washed twice before adoptive transfer. In order to
quantitatively assess the physiologic dysfunction induced
by T-cell transfer, we measured carbon monoxide (CO)
uptake and inspiratory capacity (IC) 4 d after cell transfer,
as previously described (51). Briefly, after tracheal intubation, the IC of each animal was estimated by inflation with
air to a pressure equivalent to 20 cm H2O (58, 59). The
lungs were then inflated with a volume equal to the IC of a
gas mixture containing 0.3% CO, 0.3% methane, 20% oxygen, and the balance consisting of nitrogen. The gas was
allowed to dwell for a 10 s breathhold, after which one half
of the sample was drawn off and discarded as dead space
and the other half was drawn off as an alveolar sample
(60). Three measurements were made for each animal,
and the CO uptake was determined as the ratio of CO loss
to methane loss (59, 61).
Statistical Analysis
Significant differences were determined with Student's unpaired t test or through one-way analysis of variance (ANOVA).
| |
Results |
|---|
|
|
|---|
Alveolar Epithelial-Derived Cells Are Insensitive to FasL Expressed on CD8+ T Cells
In order to explore the molecular basis of CD8+ T-cell-
mediated injury to alveolar epithelium, we developed an
in vitro system for measuring T-cell cytolysis of alveolar
epithelial-derived cells. The MLE-15 cell line, which maintains phenotypic characteristics of type II alveolar epithelial cells (52), was transfected with the class I MHC molecule Kd (the haplotype of the transgenic animals and the
T-cell clones used in these studies). The level of expression
of Kd was comparable to the expression level of the endogenous MHC class I molecule, Kq, as determined by flow
cytometry (not shown). We have previously shown that
CD8+ T cells recognize and lyse transfectant MLE-Kd cells
if the target cell is infected with the appropriate strain of
influenza virus or if exogenous peptide loading of Kd occurs with the appropriate Kd-restricted epitope, but that
no such recognition of untransfected MLE-15 cells occurs
(51). As shown in Figure 1, the recognition and cytolysis of
peptide-loaded MLE-Kd cells by the CD8+ cytolytic T-cell
clone 40-2 was completely unaffected by the anti-FasL antibody MFL3 (at 5 µg/ml). In order to demonstrate that
this antibody (5 µg/ml) was capable of completely blocking FasL-dependent lysis by clone 40-2, we used the paired
target cells L1210+ and L1210
, which are transfected with
sense and antisense Fas overexpression constructs, respectively. These cells are (not surprisingly) either very sensitive or insensitive, respectively, to FasL-triggered apoptosis (19, 54). Cao and colleagues, using the identical T-cell
clone 40-2, have previously shown that T-cell recognition of
foreign antigen triggers both the perforin and the FasL/
Fas pathways of cytotoxicity. In contrast, recognition of a
"self antigen" triggers cytolysis mediated specifically and
exclusively by FasL, with no utilization of the otherwise intact perforin-mediated pathway of cytotoxicity (54).
Therefore, this target cell pair used in our study provides a
very useful readout of perforin-independent cytotoxicity.
As shown in Figure 2, there was minimal inhibition by the
anti-FasL antibody MFL3 of recognition and cytolysis of target cells (L1210+ or L1210
) by 40-2 cells in the presence of the HA210-219 peptide, indicating significant residual perforin-mediated lysis. However, in the absence of
peptide antigen (i.e., in the presence of self antigen only),
there was no cytolysis of L1210
cells, and yet there was
significant lysis of L1210+ cells, indicating perforin-independent (FasL-mediated) cytolysis. Furthermore, the cytotoxicity of 40-2 cells toward L1210+ cells in the absence
of peptide was completely inhibited by the MFL3 antibody
at 5 µg/ml. Therefore, this concentration of the antibody
was adequate to completely inhibit the FasL-mediated cytotoxic activity of clone 40-2. Importantly, as shown in Figure 1, blockade of FasL-mediated activity by antibody did
not inhibit the lysis of MLE-Kd cells, indicating the insensitivity of these alveolar type II cells to Fas-dependent lysis.
|
|
Perforin-Independent T-Cell Cytotoxicity of Alveolar
Epithelial-Derived Cells Is Mediated Entirely by TNF-
In order to further explore the mechanisms involved in the
T-cell-mediated cytotoxicity of alveolar epithelial-derived
cells, we used an alternative strategy, utilizing CD8+ T-cell
clones from perforin-deficient animals (18). Bulk HA-specific CD8+ T cells were generated from perforin-deficient
animals (bred into the H-2d haplotype) that were immunized with A/Japan/57 influenza virus. We then produced
individual CD8+ T-cell clones from the bulk cultures by
limiting dilution (53). These T cells exhibited no cytolysis
of Fas-deficient L1210
cells, but did exhibit lysis of peptide-loaded L1210+ cells, and this perforin-independent
cytolytic activity was completely inhibited by antibody to
FasL (MFL3; not shown). We therefore tested the sensitivity of MLE-Kd cells to perforin-independent cytolysis,
using perforin-deficient T cells. As shown in Figure 3, the
CD8+ T-cell clone PKO-GV effected cytotoxicity at levels
similar to those of wild-type T cells in the presence of antigenic peptide, but showed no effect of MFL3 antibody. Interestingly, cytolysis of MLE-Kd cells by PKO-GV cells
was completely inhibited by antibody to TNF-
, which has
been shown to be expressed on CD8+ T cells, predominantly as a membrane-bound molecule (49). Several other,
independently evaluated perforin-deficient CD8+ T-cell
clones exhibited the same phenotype (not shown). These data indicate that FasL-insensitive MLE-Kd cells are unusually sensitive to TNF-
-mediated cytotoxicity by CD8+
T cells. The sensitivity of MLE-Kd cells to TNF-
is a very
uncommon phenotype: it is very difficult to demonstrate
this phenomenon in other target cells without the addition
of inhibitors of transcription or protein synthesis (62) and/or without testing for cytotoxicity over a considerably
longer assay period, usually 24 h or more (19, 49). Furthermore, the inhibition of perforin-independent cytolysis by
anti-TNF-
antibody confirms that MLE-Kd cells are resistant to apoptotic signals delivered by FasL expressed on
CD8+ T cells.
|
In order to rule out the possibility that FasL-induced
apoptosis of alveolar epithelial-derived cells plays a role in
"bystander" injury, as has been suggested with other cell
types (65, 66), we investigated the relationship between
antigen recognition of and cytotoxicity to neighboring
cells, using a transfectant cell line (BHA) as antigen-presenting cells (P815 cells expressing full length A/Japan/57
HA). Like most cells that have been studied with regard to
apoptosis (62), P815 (and BHA) cells are resistant to TNF-mediated apoptosis in the absence of protein synthesis inhibitors, and anti-FasL antibody completely blocks all cytolysis of these target cells by perforin-deficient T cells
(not shown). Figure 4 shows the results of a representative
experiment in which BHA cells (unlabeled) were used as
the antigen-presenting cells and 51Cr-labeled MLE-Kd cells
(without virus infection or peptide loading) were used as
bystander cells. Recognition of "cold" BHA cells by PKO-GV cells resulted in cytolysis of "hot" MLE-Kd cells, but
in minimal lysis in the absence of the BHA cells. The level
of cytolysis was almost identical to that produced by peptide treatment of the MLE-Kd cells (in the absence of
BHA cells). This phenomenon is clearly the result of a
specific recognition event, since untransfected (parental)
P815 cells do not activate the T cells to effect bystander cell lysis. These results also clearly indicate that the capacity to induce bystander-cell cytotoxicity is not a constitutive
phenomenon (i.e., after in vitro activation), since specific
antigen recognition in the assay is required. Importantly,
the cytolysis of bystander MLE-Kd cells induced by BHA-triggered PKO-GV cells was completely inhibited by anti-TNF-
antibody.
|
We further investigated TNF-mediated bystander injury with the wild-type CD8+ T-cell clone 40-2 as the effector cells and with A/Japan/57 influenza-infected MLE-Kd cells as the triggering cells. In these experiments, the bystander targets were either 51Cr-labeled MLE-Kd cells or 51Cr-labeled parental MLE cells (both without virus infection or peptide loading). As shown in Figure 5, there was no significant cytolysis when 40-2 cells were incubated with either the labeled uninfected MLE-Kd cells or with labeled uninfected parental (untransfected) MLE-15 cells, and there was no effect of anti-TNF antibody in either circumstance. However, the addition of unlabeled influenza-virus-infected MLE-Kd cells (at a 1:1 ratio to labeled uninfected bystanders cells) resulted in significant bystander cytotoxicity, which was independent of Kd expression by the bystander cell. As in the previous experiment, bystander-cell cytolysis was completely inhibited by anti-TNF antibody. These results suggest that this effect represents true bystander injury (i.e., cytotoxicity unrelated to peptide transfer and cross-presentation). These data also suggest that perforin does not participate in bystander injury to alveolar epithelial-derived cells, in contrast with the primary role played by perforin in direct cytolysis of virus-infected MLE-Kd cells by wild-type T cells (data not shown).
|
Alveolar Epithelial-Derived Cells Express Functional Fas
Although others have demonstrated Fas expression by the parental (MLE-15) cell line (45, 67, 68), our results as described earlier could be explained by the loss of Fas expression that might have occurred during transfection, selection, and cloning of the MLE-Kd cell. Other investigators have reported induction of apoptosis of alveolar epithelial cells, including MLE-15 cells, with the agonistic anti-Fas antibody Jo-2 (44, 45). In order to confirm that MLE-Kd cells express functional Fas, we investigated whether Jo-2 could induce apoptosis in MLE-Kd cells. We were unable to detect cytolysis of MLE-Kd cells induced by Jo-2 antibody in standard 6-h 51Cr-release assays, although this was not surprising in view of our observations with other cell lines (even those that are functionally Fas-sensitive) in standard 51Cr-release assays (unpublished results). Therefore we took advantage of a more sensitive DNA fragmentation assay (55) that has been used previously to measure Fas-mediated cell death (54). This assay has the advantage of detecting earlier events in apoptosis, occurring before the membrane disruption necessary for 51Cr-release (55). As shown in Figure 6, MLE-Kd cells exhibited significant DNA fragmentation by 6 h after crosslinking with the Jo-2 antibody. This effect in MLE-Kd cells was not enhanced by the addition of protein G, even though significant enhancement of DNA fragmentation occurred in L1210+ cells upon addition of protein G. Spontaneous apoptosis (medium alone) was less than 5% by 6 h. An isotype-matched control hamster antibody (MFL3) had no effect, at a variety of concentrations, with or without protein G (not shown). Similarly, protein G alone had no effect. These data strongly suggest that Fas is present and capable of triggering the apoptotic cascade in MLE-Kd cells, although the functional significance of this remains unclear.
|
MLE-Kd Cells and Primary Type II Alveolar
Epithelial Cells Are Susceptible to Apoptosis
Induced by Soluble TNF-
Although anti-TNF antibody completely inhibited the cytolysis of MLE-Kd cells by perforin-deficient CD8+ T cells,
the data do not reveal whether this was due to membrane-bound or secreted TNF-
. To investigate whether MLE-Kd cells are susceptible to apoptosis triggered by soluble
TNF-
, we performed DNA fragmentation assays after 6 h
of treatment with varying doses of TNF-
. As shown in
Figure 7A, soluble TNF-
induced significant DNA fragmentation in MLE-Kd cells as compared with media controls, and the effect reached a plateau at 1,000 U/ml. In order to confirm that the susceptibility of the MLE-Kd cells
to cytotoxicity mediated by soluble TNF is not unique to this type II alveolar cell line, but rather reflects an intrinsic property of untransformed lung epithelial cells, we isolated primary murine type II pneumocytes for use in correlative studies. As shown in Figure 7B, soluble TNF-
(1,000 U/ml) induced significant apoptosis in primary type
II cells as compared with controls (P < 0.05). This suggests
that the TNF-sensitivity of MLE-Kd cells is not a unique
feature of this particular transformed cell line.
|
Perforin-Deficient CD8+ T Cells Induce Significant
Lung Injury In Vivo That Is Independent of Fas and
Dependent upon TNF-
We have previously reported that wild-type, influenza-virus-
specific CD8+ T cells induce significant lung injury upon
being adoptively transferred into transgenic mice expressing influenza HA in their type II alveolar epithelial cells
(50, 51). This injury is characterized by significant loss of
alveolar epithelial cells, as well as by restrictive physiology, significant impairment of gas exchange, and death
(51). We also demonstrated that the impairment in gas exchange, as determined by CO uptake, correlated especially strongly with the histologic and clinical abnormalities observed in these mice (51). In order to determine the
relative contribution of the perforin-independent mediators FasL and TNF-
to T-cell cytotoxicity and injury in
vivo, we performed adoptive transfer of the perforin-deficient (FasL+, TNF-
+), HA-specific CD8+ T-cell clone
PKO-GV into three recipient groups: wild-type HA+ mice,
Fas-deficient/HA+ mice, and HA
control littermates. As
shown in Figure 8, there was a significant decrement in CO
uptake in HA+ transgenic recipients as compared with
their HA
littermates (which was similar to that measured
in animals that had not received cells; data not shown). Interestingly, there was no abrogation of injury by PKO-GV
T cells in the absence of Fas expression in the Fas-deficient recipients (lpr/HA+ mice). However, preincubation
of PKO-GV T cells with anti-TNF antibody resulted in
complete abrogation of lung injury, further suggesting the
Fas-independent nature of this (perforin-independent) CD8+ T-cell-mediated injury process. Histologically, the
lung sections harvested at Day 4 from lpr/HA+ animals
that received anti-TNF-antibody-treated T cells were indistinguishable from the lungs of HA
recipients (data not
shown); there was minimal perivascular and peribronchiolar cuffing without significant alveolar infiltration, resembling that previously described (50, 51). No difference was
observed histologically between the HA+ and the lpr/HA+
recipients of PKO-GV T cells, and both showed significant
infiltration of the alveolar walls and spaces, resembling
that previously described (50, 51). Prior to T-cell transfer,
lpr/HA+ mice were indistinguishable from normal (HA
)
mice both histologically and physiologically (data not
shown). The 4-d time point was chosen on the basis of previous data (51) as well as from the tempo of progression of
clinical illness observed in these animals.
|
| |
Discussion |
|---|
|
|
|---|
Many interstitial lung diseases are in part characterized by varying degrees of CD8+ T-cell (in addition to other inflammatory cell) infiltration of the alveolar septae, spaces, or both. We have previously shown that antigen-specific CD8+ T-cell recognition by a single clonal population and of a single epithelial "autoantigen," is in and of itself sufficient to trigger an inflammatory cascade that results both histologically and physiologically in the clinical picture of interstitial pneumonia (50, 51). Adoptive transfer of 107 T cells resulted in a complete loss of alveolar epithelial cells, resembling the epithelial denuding seen in disease states associated pathologically with diffuse alveolar damage (such as acute interstitial pneumonia). T cells express a range of cytotoxic and noncytotoxic effector functions, which have been intensively investigated in the context of viral infection. CD8+ T cells are particularly associated with cytotoxic activity when they recognize class I MHC-restricted peptide epitopes, such as viral antigens. The major mechanisms involved in CD8+ T cell cytotoxicity have been elucidated in vitro, and several groups have clearly shown that the perforin/granzyme pathway and the Fas- FasL pathway account for all of these cells' in vitro cytolytic effect as observed in cytotoxicity assays using conventional target cells, which are generally of hematopoetic origin (12, 13, 15). The role of Fas in T-cell suicide and fratricide is well described (20, 69), although Fas expression has recently been reported in a number of nonhematopoetic tissues, such as liver (26) and lung (37). The role of Fas in the expression of immune effector activity (or injury) in these tissues is unclear, although it has been suggested that Fas may play a role in immunity to virus infection (37). Several studies have suggested that Fas may participate in immune injury in chronic inflammation of the liver (28) and lung (38, 40). There is so far no direct evidence that Fas-mediated apoptosis plays a role in lung injury caused specifically by FasL-expressing T cells.
Experimentally, alveolar epithelial-derived cells may
be triggered to undergo apoptosis upon ligation of Fas
with Jo-2 antibody (44, 45), and intratracheal administration of this antibody in mice results in significant lung injury (43). We have confirmed Fas expression in the lungs
of HA+ transgenic mouse lines by reverse transcription-
PCR, and in the alveolar epithelium of these animals by
in situ hybridization (unpublished observations). It was
therefore somewhat surprising to observe that the absence
of Fas expression in lpr/HA+ transgenic mice did not abrogate the injury produced by T-cell transfer, even in the absence of perforin. It was also surprising to observe that
MLE-Kd cells were totally insensitive to the effects of
FasL expressed by activated T cells, whereas neutralizing
antibody to FasL completely inhibited cytotoxicity to Fas-sensitive L1210+ target cells by wild-type CD8+ T cells of
clone 40-2 (without peptide) and by T-cells of the perforin-deficient clone PKO-GV (with peptide). In this experiment, anti-FasL antibody completely eliminated all
FasL-mediated cytotoxicity by both 40-2 cells and PKO-GV cells against L1210+ cells, but had no effect on the cytolysis of MLE-Kd cells. Interestingly, neutralizing antibody to TNF-
completely inhibited all cytotoxicity to
MLE-Kd cells by the perforin-deficient T-cell clone PKO-GV. The lung injury observed in vivo in lpr/HA+ mice after transfer of perforin-deficient T cells, and its abrogation by pretreatment of such T cells with antibody to TNF-
,
further support the hypothesis that alveolar epithelial cells
may be insensitive to FasL-triggered apoptosis. This in
vivo result is consistent with our in vitro observation that
perforin-independent type II cell cytotoxicity is mediated
exclusively by TNF-
(though we cannot formally exclude
the possibility that the carryover of a small amount of anti-TNF may also have blocked TNF-
secreted in vivo from
non-T-cell [host] sources despite the washing of T cells after preincubation). Nevertheless the effect of pretreatment with this antibody, as well as the significant injury
observed in Fas-deficient lpr/HA+ mice, argue against an
important effect of FasL on the injury process.
MLE-Kd cells were also susceptible to cytotoxicity triggered by soluble TNF-
, although our data do not address
the quantitative importance of this contribution. This observation nevertheless reflects a qualitatively unusual phenotype, which may have important implications in the
lung. TNF receptor engagement simultaneously triggers
several parallel signaling pathways, including the proapoptotic activation of the caspase cascade, but also the induction of transcription of antiapoptotic gene products mediated primarily by nuclear factor-
B (70). In nearly all cells
examined, induction of apoptosis by TNF requires treatment with actinomycin D or cycloheximide in order to inhibit the transcription or translation of antiapoptotic gene
products, especially in short-term assays (62). In order to
confirm this phenotype in untransformed type II pneumocytes, we tested the sensitivity of primary alveolar type
II cell isolates for sensitivity to apoptosis triggered by soluble TNF-
, and observed a similar effect. As noted earlier,
our data do not address the quantitative physiologic significance of this effect, since we used a saturating dose of
TNF-
. However, the qualitative effect was quite evident.
Not unexpectedly, there was a moderate degree of spontaneous apoptosis in primary type II cells that occurred over
a period of time after they were removed from their normal anchorage to basement membrane.
It has been reported for other cell types that the level of
Fas expression does not correlate with biologic responsiveness as determined by induction of apoptosis with Jo-2
antibody (71). This strongly suggests that mechanisms may
exist to tightly regulate programmed cell death in most cell
types. Though MLE-Kd cells, upon exposure to FasL, are
relatively resistant to Fas-mediated apoptosis, these cells
clearly express functional Fas, as indicated by the induction of DNA fragmentation by the Jo-2 antibody in a more
sensitive assay. These unknown regulatory mechanisms that tightly control programmed cell death may have important
ramifications with regard to inflammatory lung disease, as
may the unusual sensitivity of alveolar epithelial-derived
cells to TNF-
expressed by CD8+ T cells. Numerous
other factors may contribute to the regulation of alveolar
epithelial-cell susceptibility to Fas-mediated apoptosis. For
example, other cell types, such as T cells, appear to be resistant to Fas-induced apoptosis during the S phase of the
cell cycle (72), and this resistance may correlate with the
inability to recruit caspase-8 to the death-inducing signal
complex (DISC) early after T cell stimulation (73). There
are also suggestions in other cell types that Fas may participate in transducing signals for nonapoptotic cellular functions, such as proliferation in keratinocytes (74) and angiogenesis (75), as is the case with other members of the TNF
receptor family (76).
The findings in this study lead to two conclusions: (1)
that MLE-Kd cells are relatively resistant to FasL-mediated Fas-dependent cytotoxicity affected by CD8+ T cells,
in contrast to the effect of TNF-
; and (2) that TNF-
expressed by CD8+ T cells accounts entirely for the perforin-independent cytotoxic effect of MLE-Kd cells. We have
also shown that alveolar epithelial-derived cells, as well as
primary type II pneumocytes, are sensitive to the apoptotic signal generated by soluble TNF-
. Data obtained after adoptive transfer of perforin-deficient CD8+ T cells
into Fas-deficient (lpr/HA+) mice expressing HA exclusively
in type II cells in vivo (50) are also consistent with these observations, suggesting that the phenotype of MLE-Kd cells
may reflect that of alveolar type II cells in general. The
sensitivity of alveolar cells to TNF expressed (or produced) by CD8+ T cells may have greater importance in
bystander than in direct cytotoxicity, since we have shown
that bystander-cell lysis is perforin-independent (and therefore TNF-dependent). The mechanisms underlying the unusual sensitivity of alveolar epithelial cells to TNF remain to
be elucidated, but the observations described earlier raise
the possibility that although perforin-mediated apoptosis
may represent a primary antiviral effector mechanism of T
cells, TNF-
may play a role in the lung injury that occurs during (and possibly after) a viral respiratory infection.
There is a further potentially important consequence of
the preferential sensitivity of alveolar epithelial cells to
TNF-
as compared with FasL. In contrast to ligation of
Fas, ligation of TNF receptors results in activation of
proinflammatory signaling, leading to transcription of a
host of cytokines and chemokines (62). For example, human alveolar epithelial cell lines have been reported to express IL-8, a potent neutrophil chemoattractant, upon
exposure to TNF-
(48). This raises the possibility that alveolar epithelial cells may be predisposed to nonspecific
amplification of inflammatory processes mediated by
CD8+ T cells, as we have observed in vivo in our model of
T-cell-mediated lung injury (51). We previously demonstrated that from 4 to 5 d after the initial T-cell-mediated
insult to alveolar cells, the inflammatory infiltrate consists
primarily of host macrophages. These cells are also capable of producing TNF-
(as well as other cytokines), which
may serve to further amplify the inflammatory cascade. Detailed investigation will be required to dissect the mechanisms controlling the amplification of inflammation in the lung, which may be critical in understanding the pathogenesis of interstitial lung diseases.
| |
Footnotes |
|---|
Address correspondence to: Richard I. Enelow, M.D., Department of Medicine, Box 546, University of Virginia Health Sciences Center, Charlottesville, VA 22908. E-mail: enelow{at}virginia.edu
(Received in original form October 9, 1998 and in revised form March 4, 1999).
Abbreviations: Fas ligand, FasL; hemagglutinin, HA; tumor necrosis factor-
, TNF-
.
Acknowledgments: This work was performed in conjunction with the Academic Enhancement Program for Gene Transfer in the Cardiovascular System at the University of Virginia, whose support the authors gratefully acknowledge. They also gratefully acknowledge the critical assistance of Dr. Dudley F. Rochester for many helpful discussions and much advice. The work was supported by research grants HL58660 (R.I.E.), HL33391, and AI15608 (T.J.B.) from the United States Public Health Service, as well as by grants from the American Lung Association of Virginia and the American Heart Association of Virginia. The continuing support of the Beirne B. Carter Foundation is gratefully acknowledged.
| |
References |
|---|
|
|
|---|
1. Costabel, U., H. Teschler, and J. Guzman. 1992. Bronchiolitis obliterans organizing pneumonia (BOOP): the cytological and immunocytological profile of bronchoalveolar lavage. Eur. Respir. J. 5: 791-797 [Abstract].
2. Katzenstein, A. 1997. Katzenstein and Askin's Surgical Pathology of Non-Neoplastic Lung Disease. W.B. Saunders, Philadelphia.
3. Kradin, R. L., M. B. Divertie, R. B. Colvin, J. Ramirez, J. Ryu, H. A. Carpenter, and A. K. Bhan. 1986. Usual interstitial pneumonitis is a T-cell alveolitis. Clin. Immunol. Immunopathol. 40: 224-235 [Medline].
4. Leatherman, J., A. Michael, B. Schwartz, and J. Hoidal. 1984. Lung T cells in hypersensitivity pneumonitis. Ann. Intern. Med. 100: 390-396 .
5. Lukacher, A. E., L. A. Morrison, V. L. Braciale, and T. J. Braciale. 1986. T lymphocyte function in recovery from experimental viral infection: the influenza model. In Mechanisms of Host Resistance to Infectious Agents, Tumors, and Allografts. R. M. Steinman, editor. Rockefeller University Press, New York. 233-254.
6. Yap, K. L., T. J. Braciale, and G. L. Ada. 1979. Role of T-cell function in recovery from murine influenza infection. Cell. Immunol. 43: 341-351 [Medline].
7. Wells, M. A., P. Albrecht, and F. A. Ennis. 1981. Recovery from a viral respiratory infection: I. Influenza pneumonia in normal and T-deficient mice. J. Immunol. 126: 1036-1041 [Abstract].
8. Couch, R. B., and J. Kasel. 1983. Immunity to influenza in man. Annu. Rev. Microbiol. 37: 529-549 [Medline].
9. Ada, G., and P. Jones. 1986. The immune responses to influenza infection. Curr. Top. Microbiol. Immunol. 128: 1-54 [Medline].
10. Ada, G., and P. Jones. 1987. The cell-mediated and humoral responses to influenza virus infection in the mouse lung. Adv. Exp. Med. Biol. 216B: 1033-1042.
11. Andrew, M. E., V. L. Braciale, T. J. Henkel, J. A. Hatch, and T. J. Braciale. 1985. Stable expression of cytolytic activity by influenza virus-specific cytotoxic T lymphocytes. J. Immunol. 135: 3520-3523 [Abstract].
12. Henkart, P. 1993. Cytotoxic Cells. Birkhauser, Boston. 9-45.
13. Kojima, H., N. Shiohara, S. Hanaoka, Y. Shirota, Y. Takagaki, H. Ohno, T. S. Katayama, H. Yagita, K. Okumura, Y. Shinkai, F. Alt, A. Matsuzawa, S. Yonehara, and H. Takayama. 1994. Two distinct pathways of specific killing revealed by perforin mutant cytotoxic T lymphocytes. Immunity 1: 357-364 [Medline].
14. Braciale, T. J., C. F. Mojcik, and V. Hauptfeld. 1982. Target-cell recognition by cloned lines of influenza virus-specific cytotoxic T lymphocytes: selective inhibition by a monoclonal H-2-specific antibody. Immunogenetics 15: 41-52 [Medline].
15. Henkart, P.. 1994. Lymphocyte-mediated cytotoxicity: two pathways and multiple effector molecules. Immunity 1: 343-346 [Medline].
16.
Kagi, D.,
F. Vignaux,
B. Ledermann,
K. Burki,
V. Depraetere,
S. Nagata,
H. Nengartner, and
P. Golstein.
1994.
Fas and perforin as major mechanisms
of T cell-mediated cytotoxicity.
Science
265:
528-530
17. Lowin, B., M. Hahne, C. Mattmann, and J. Tschopp. 1994. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 370: 650-652 [Medline].
18.
Walsh, C.,
M. Matloubian,
C. Lui,
R. Udea,
C. Kurahara,
J. Christiansen,
M. Huang,
J. Young,
R. Ahmed, and
W. Clark.
1994.
Immune function
in mice lacking the perforin gene.
Proc. Natl. Acad. Sci. USA
91:
10854-10858
19. Walsh, C. M., A. A. Glass, V. Chiu, and W. R. Clark. 1994. The role of the Fas lytic pathway in a perforin-less CTL hybridoma. J. Immunol. 153: 2506-2514 [Abstract].
20.
Alderson, M. R.,
T. W. Tough,
S. T. Davis,
S. Braddy,
B. Falk,
K. A. Schooley,
R. G. Goodwin,
C. A. Smith,
F. Ramsdell, and
D. H. Lynch.
1995.
Fas ligand mediates activation-induced cell death in human T lymphocytes.
J. Exp. Med.
181:
71-77
21. Brunner, T., R. J. Mogil, D. LaFace, N. J. Yoo, A. Mahboubi, F. Echeverri, S. J. Martin, W. R. Force, D. H. Lynch, C. F. Ware, and D. R. Green. 1995. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 373: 441-444 [Medline].
22. Crispe, I.. 1994. Fatal interactions: Fas-induced apoptosis of mature T cells. Immunity 1: 347-349 [Medline].
23. Dhein, J., H. Walczak, C. Baumler, K. Debatin, and P. H. Krammer. 1995. Autocrine T-cell suicide mediated by APO-1 (Fas/CD95). Nature 3734: 438-448 .
24. Ettinger, R., D. Panka, J. Wang, B. Stanger, S. Ju, and A. Rothstein. 1995. Fas ligand-mediated cytotoxicity is directly responsible for apoptosis of normal CD4+ T cells responding to a bacterial superantigen. J. Immunol. 154: 4302-4308 [Abstract].
25. Lynch, D. H., F. Ramsdell, and M. R. Alderson. 1995. Fas and FasL in the homeostatic regulation of immune responses. Immunol. Today 16: 569-574 [Medline].
26. Seino, K., N. Kayagaki, K. Takeda, K. Fukao, K. Okumura, and H. Yagita. 1997. Contribution of Fas ligand to T cell-mediated hepatic injury in mice. Gastroenterology 113: 1315-1322 [Medline].
27. Pensati, L., A. Costanzo, A. Ianni, D. Accapezzato, R. Iorio, G. Natoli, R. Nisini, C. Almerighi, C. Balsano, P. Vajro, A. Vegnente, and M. Levrero. 1997. Fas/Apo1 mutations and autoimmune lymphoproliferative syndrome in a patient with type 2 autoimmune hepatitis. Gastroenterology 113: 1384-1389 [Medline].
28. Luo, K. X., Y. F. Zhu, L. X. Zhang, H. T. He, X. S. Wang, and L. Zhang. 1997. In situ investigation of Fas/FasL expression in chronic hepatitis B infection and related liver diseases. J. Viral Hepatol. 4: 303-307 . [Medline]
29. Hayashi, N., and E. Mita. 1997. Fas system and apoptosis in viral hepatitis. J. Gastroenterol. Hepatol. 12: S223-S226 [Medline].
30.
Galle, P.,
W. Hofmann,
H. Walczak,
H. Schaller,
G. Otto,
W. Stremmel,
P. Krammer, and
L. Runkel.
1995.
Involvement of the CD95 (APO-1/Fas)
receptor and ligand in liver damage.
J. Exp. Med.
182:
1223-1230
31. Takehara, T., N. Hayashi, E. Mita, T. Kanto, T. Tatsumi, Y. Sasaki, A. Kasahara, and M. Hori. 1998. Delayed Fas-mediated hepatocyte apoptosis during liver regeneration in mice: hepatoprotective role of TNF-alpha. Hepatology 27: 1643-1651 [Medline].
32.
Schneider, P.,
N. Holler,
J. L. Bodmer,
M. Hahne,
K. Frei,
A. Fontana, and
J. Tschopp.
1998.
Conversion of membrane-bound Fas(CD95) ligand to its
soluble form is associated with downregulation of its proapoptotic activity
and loss of liver toxicity.
J. Exp. Med.
187:
1205-1213
33.
Chandler, J. M.,
G. M. Cohen, and
M. MacFarlane.
1998.
Different subcellular distribution of caspase-3 and caspase-7 following Fas-induced apoptosis in mouse liver.
J. Biol. Chem.
273:
10815-10818
34. French, L. E., and J. Tschopp. 1997. Thyroiditis and hepatitis: Fas on the road to disease. Nature Med. 3: 387-388 [Medline].
35.
Giordano, C.,
G. Stassi,
R. De Maria,
M. Todaro,
P. Richiusa,
G. Papoff,
G. Ruberti,
M. Bagnasco,
R. Testi, and
A. Galluzzo.
1997.
Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis
(see comments).
Science
275:
960-963
36.
Itoh, N.,
A. Imagawa,
T. Hanafusa,
M. Waguri,
K. Yamamoto,
H. Iwahashi,
M. Moriwaki,
H. Nakajima,
J. Miyagawa,
M. Namba,
S. Makino,
S. Nagata,
N. Kono, and
Y. Matsuzawa.
1997.
Requirement of Fas for the development of autoimmune diabetes in nonobese diabetic mice.
J. Exp. Med.
186:
613-618
37.
Gochuico, B. R.,
K. M. Miranda,
E. M. Hessel,
J. J. De Bie,
A. J. Van Oosterhout,
W. W. Cruikshank, and
A. Fine.
1998.
Airway epithelial Fas ligand
expression: potential role in modulating bronchial inflammation.
Am. J. Physiol.
274:
L444-L449
38. Kazufumi, M., N. Sonoko, K. Masanori, I. Takateru, and O. Akira. 1997. Expression of bcl-2 protein and APO-1 (Fas antigen) in the lung tissue from patients with idiopathic pulmonary fibrosis. Microsc. Res. Tech. 38: 480-487 [Medline].
39.
Spinozzi, F.,
M. Fizzotti,
E. Agea,
S. Piattoni,
S. Droetto,
A. Russano,
N. Forenza,
G. Bassotti,
F. Grignani, and
A. Bertotto.
1998.
Defective expression of Fas messenger RNA and Fas receptor on pulmonary T cells
from patients with asthma.
Ann. Intern. Med.
128:
363-369
40. Tomokuni, A., T. Aikoh, T. Matsuki, Y. Isozaki, T. Otsuki, S. Kita, H. Ueki, M. Kusaka, T. Kishimoto, and A. Ueki. 1997. Elevated soluble Fas/APO-1 (CD95) levels in silicosis patients without clinical symptoms of autoimmune diseases or malignant tumours. Clin. Exp. Immunol. 110: 303-309 [Medline].
41. Nomoto, Y., K. Kuwano, N. Hagimoto, R. Kunitake, M. Kawasaki, and N. Hara. 1997. Apoptosis and Fas/Fas ligand mRNA expression in acute immune complex alveolitis in mice. Eur. Respir. J. 10: 2351-2359 [Abstract].
42. Hagimoto, N., K. Kuwano, Y. Nomoto, R. Kunitake, and N. Hara. 1997. Apoptosis and expression of Fas/Fas ligand mRNA in bleomycin-induced pulmonary fibrosis in mice. Am. J. Respir. Cell Mol. Biol. 16: 91-101 [Abstract].
43.
Hagimoto, N.,
K. Kuwano,
H. Miyazaki,
R. Kunitake,
M. Fujita,
M. Kawasaki,
Y. Kaneko, and
N. Hara.
1997.
Induction of apoptosis and pulmonary fibrosis in mice in response to ligation of Fas antigen.
Am. J. Respir.
Cell Mol. Biol.
17:
272-278
44. Gochuico, B. R., M. C. Williams, and A. Fine. 1997. Simultaneous in situ hybridization and TUNEL to identify cells undergoing apoptosis. Histochem. J. 29: 413-418 [Medline].
45.
Fine, A.,
N. L. Anderson,
T. L. Rothstein,
M. C. Williams, and
B. R. Gochuico.
1997.
Fas expression in pulmonary alveolar type II cells.
Am. J. Physiol.
273:
L64-L71
46. Shanley, T. P., H. Schmal, H. P. Friedl, M. L. Jones, and P. A. Ward. 1995. Role of macrophage inflammatory protein-1 alpha (MIP-1 alpha) in acute lung injury in rats. J. Immunol. 154: 4793-4802 [Abstract].
47.
Peschon, J. J.,
D. S. Torrance,
K. L. Stocking,
M. B. Glaccum,
C. Otten,
C. R. Willis,
K. Charrier,
P. J. Morrissey,
C. B. Ware, and
K. M. Mohler.
1998.
TNF receptor-deficient mice reveal divergent roles for p55 and p75
in several models of inflammation.
J. Immunol.
160:
943-952
48. Standiford, T. J., S. L. Kunkel, M. A. Basha, S. W. Chensue, J. P. D. Lynch, G. B. Toews, J. Westwick, and R. M. Strieter. 1990. Interleukin-8 gene expression by a pulmonary epithelial cell line: a model for cytokine networks in the lung. J. Clin. Invest. 86: 1945-1953 .
49. Ratner, A., and W. R. Clark. 1993. Role of TNF-alpha in CD8+ cytotoxic T lymphocyte-mediated lysis. J. Immunol. 150: 4303-4314 [Abstract].
50. Enelow, R., M. Stoler, A. Srikiatkhachorn, C. Kerlakian, S. Agersborg, J. Whitsett, and T. Braciale. 1996. A lung-specific neo-antigen elicits specific CD8+ T cell tolerance with preserved CD4+ T cell reactivity. J. Clin. Invest. 98: 914-922 [Medline].
51. Enelow, R. I., A. Z. Mohammed, M. H. Stoler, J. S. Young, Y. H. Lou, and T. J. Braciale. 1998. Experimental T cell-mediated lung disease: structural and functional consequences of alveolar cell recognition by CD8+ T lymphocytes. J. Clin. Invest. 102: 1653-1661 [Medline].
52.
Wikenheiser, K.,
D. Vorbroker,
W. Rice,
J. Clark,
C. Bachurski,
H. Oie, and
J. Whitsett.
1993.
Production of immortalized distal respiratory epithelial cell lines from surfactant protein C/simian virus 40 large tumor antigen transgenic mice.
Proc. Natl. Acad. Sci. USA
90:
11029-11033
53. Graham, M., T. Braciale, and V. Braciale. 1996. Use of antiviral T-lymphocyte clones to characterize antigen presentation and T-lymphocyte subsets. Methods: A Companion to Methods in Enzymology 9:439-444.
54. Cao, W., S. S. Tykodi, M. T. Esser, V. L. Braciale, and T. J. Braciale. 1995. Partial activation of CD8+ T cells by a self-derived peptide. Nature 378: 295-298 [Medline].
55. Matzinger, P.. 1991. The JAM test: a simple assay for DNA fragmentation and cell death. J. Immunol. Methods 145: 185-192 [Medline].
56. Corti, M., A. R. Brody, and J. H. Harrison. 1996. Isolation and primary culture of murine alveolar type II cells. Am. J. Respir. Cell Mol. Biol. 14: 309-315 [Abstract].
57.
Maldonado, M. A.,
R. A. Eisenberg,
E. Roper,
P. L. Cohen, and
B. L. Kotzin.
1995.
Greatly reduced lymphoproliferation in lpr mice lacking major histocompatibility complex class I.
J. Exp. Med.
181:
641-648
58. Hartsfield, C., D. Lipke, Y. Lai, D. Cohen, and M. Gillespie. 1997. Pulmonary mechanical and immunologic dysfunction in a murine model of AIDS. Am. J. Physiol. 272 (Lung Cell Mol. Physiol. 16):L699-L706.
59. Takezawa, J., F. Miller, and J. O'Neil. 1980. Single-breath diffusing capacity and lung volumes in small laboratory mammals. J. Appl. Physiol.: Respir. Environ. Exerc. Physiol. 48:1052-1059.
60.
Sabo, J.,
E. Kimmel, and
L. Diamond.
1983.
Effects of the Clara cell toxin,
4-ipomeanol, on pulmonary function in rats.
J. Appl. Physiol.
54:
337-344
61. Depledge, M., C. Collis, and A. Barrett. 1981. A technique for measuring carbon monoxide uptake in mice. Int. J. Radiat. Oncol. Biol. Phys. 7: 485-489 [Medline].
62.
Ashkenazi, A., and
V. M. Dixit.
1998.
Death receptors: signaling and modulation.
Science
281:
1305-1308
63. Binder, C., L. Binder, M. Kroemker, M. Schulz, and W. Hiddemann. 1997. Influence of cycloheximide-mediated downregulation of glucose transport on TNF alpha-induced apoptosis. Exp. Cell Res. 236: 223-230 [Medline].
64.
Sanchez-Alcazar, J. A.,
J. Ruiz-Cabello,
I. Hernandez-Munoz,
P. S. Pobre,
P. de la Torre,
E. Siles-Rivas,
I. Garcia,
O. Kaplan,
M. T. Munoz-Yague, and
J. A. Solis-Herruzo.
1997.
Tumor necrosis factor-alpha increases ATP
content in metabolically inhibited L929 cells preceding cell death.
J. Biol.
Chem.
272:
30167-30177
65.
Smyth, M. J.,
E. Krasovskis, and
R. W. Johnstone.
1998.
Fas ligand-mediated lysis of self bystander targets by human papillomavirus-specific
CD8(+) cytotoxic T lymphocytes.
J. Virol.
72:
5948-5954
66. Kojima, H., K. Eshima, H. Takayama, and M. V. Sitkovsky. 1997. Leukocyte function-associated antigen-1-dependent lysis of Fas+ (CD95+/Apo-1+) innocent bystanders by antigen-specific CD8+ CTL. J. Immunol. 159: 2728-2734 [Abstract].
67. Fine, A., and N. Anderson. 1996. Expression, function and regulation of alveolar type II cell Fas. Am. J. Respir. Crit. Care Med. 153: A537 . (Abstr.) .
68. Pang, H., K. Miranda, and A. Fine. 1998. Sp3 regulates fas expression in lung epithelial cells. Biochem. J. 333: 209-213 .
69. Lynch, D. H.. 1994. Biology of Fas. Circulatory Shock 44: 63-66 [Medline].
70.
Wang, C. Y.,
M. W. Mayo,
R. G. Korneluk,
D. V. Goeddel, and
A. S. Baldwin.
1998.
NF-
B antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation.
Science
281:
1680-1683
71.
Owen-Schaub, L. B.,
R. Radinsky,
E. Kruzel,
K. Berry, and
S. Yonehara.
1994.
Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and
bcl-2 are not predictive of biological responsiveness.
Cancer Res.
54:
1580-1586
72. Dao, T., J. W. Huleatt, R. Hingorani, and I. N. Crispe. 1997. Specific resistance of T cells to CD95-induced apoptosis during S phase of the cell cycle. J. Immunol. 159: 4261-4267 [Abstract].
73. Peter, M. E., F. C. Kischkel, C. G. Scheuerpflug, J. P. Medema, K. M. Debatin, and P. H. Krammer. 1997. Resistance of cultured peripheral T cells towards activation-induced cell death involves a lack of recruitment of FLICE (MACH/caspase 8) to the CD95 death-inducing signaling complex. Eur. J. Immunol. 27: 1207-1212 [Medline].
74.
Freiberg, R. A.,
D. M. Spencer,
K. A. Choate,
P. D. Peng,
S. L. Schreiber,
G.R. Crabtree, and
P.A. Khavari.
1996.
Specific triggering of the Fas signal
transduction pathway in normal human keratinocytes.
J. Biol. Chem.
271:
31666-31669
75.
Biancone, L.,
A. D. Martino,
V. Orlandi,
P. G. Conaldi,
A. Toniolo, and
G. Camussi.
1997.
Development of inflammatory angiogenesis by local stimulation of Fas in vivo.
J. Exp. Med.
186:
147-152
76.
Beutler, B., and
C. Van Huffel.
1994.
Unraveling function in the TNF ligand
and receptor family.
Science
264:
667-668
This article has been cited by other articles: